Literature DB >> 17349336

Low molecular weight heparin suppresses tumor necrosis factor expression from deep vein thrombosis.

John Alfred Carr1, Jae-Sung Cho.   

Abstract

Prior investigations have shown that low molecular weight heparin (LMWH) possesses anti-inflammatory properties in addition to its anticoagulant effects. The physiology of this anti-inflammatory mechanism is poorly understood. Experiments were performed to assess the in vivo anti-inflammatory effects of LMWH in a rat model of deep vein thrombosis (DVT). Sprague-Dawley rats were divided into three groups and underwent laparotomy and inferior vena cava (IVC) ligation directly below the renal veins to induce thrombosis. Twenty-four hours later, intraluminal clot was confirmed at repeat laparotomy using an electromagnetic flowmeter and visual inspection. An intravenous infusion of LMWH or urokinase or no infusion (control) was then performed. Subcutaneous LMWH was given postoperatively to the heparin group. Twenty-four hours after the second operation, the animals were killed, the IVC harvested, the cells from the IVC purified, and cytokine measurements done. The LMWH group showed an overall statistically significant decrease in tumor necrosis factor-alpha (TNF-alpha) levels compared to both the control and urokinase groups by analysis of variance (918 pg/mL vs. 1,345 and 1,623, respectively; P = 0.001). To ensure accuracy, individual pairwise comparisons were performed, which also showed statistically significant TNF-alpha suppression by LMWH compared to control (P = 0.015) and urokinase (P = 0.0009). Treatment of DVT with LMWH causes suppression of TNF-alpha expression. This may, in part, explain its anti-inflammatory effects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17349336     DOI: 10.1016/j.avsg.2006.07.003

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  6 in total

1.  Editor's Spotlight/Take 5: CT pulmonary angiography after total joint arthroplasty: overdiagnosis and iatrogenic harm?

Authors:  James A Browne
Journal:  Clin Orthop Relat Res       Date:  2013-09-27       Impact factor: 4.176

2.  Low-molecular-weight heparin modulates vein wall fibrotic response in a plasminogen activator inhibitor 1-dependent manner.

Authors:  Andrea T Obi; Jose A Diaz; Nicole L Ballard-Lipka; Karen J Roelofs; Diana M Farris; Daniel A Lawrence; Peter K Henke; Thomas W Wakefield
Journal:  J Vasc Surg Venous Lymphat Disord       Date:  2014-10-01

3.  Vein wall re-endothelialization after deep vein thrombosis is improved with low-molecular-weight heparin.

Authors:  Daria K Moaveni; Erin M Lynch; Cathy Luke; Vikram Sood; Gilbert R Upchurch; Thomas W Wakefield; Peter K Henke
Journal:  J Vasc Surg       Date:  2008-03       Impact factor: 4.268

Review 4.  Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease.

Authors:  Esther J van Zuuren; Zbys Fedorowicz
Journal:  Cochrane Database Syst Rev       Date:  2015-12-18

Review 5.  Cytokines, Adhesion Molecules, and Matrix Metalloproteases as Predisposing, Diagnostic, and Prognostic Factors in Venous Thrombosis.

Authors:  Knut A Mosevoll; Silje Johansen; Øystein Wendelbo; Ina Nepstad; Øystein Bruserud; Håkon Reikvam
Journal:  Front Med (Lausanne)       Date:  2018-05-22

Review 6.  Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review.

Authors:  Jaume Alijotas-Reig; Enrique Esteve-Valverde; Cristina Belizna; Albert Selva-O'Callaghan; Josep Pardos-Gea; Angela Quintana; Arsene Mekinian; Ariadna Anunciacion-Llunell; Francesc Miró-Mur
Journal:  Autoimmun Rev       Date:  2020-05-03       Impact factor: 9.754

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.